Affordable Access

Access to the full text

3-Deoxyglucosone as a Potential Agent That Alters IgG Protein Through Advanced Glycation End Products

Authors
  • Ashraf, J. M.1, 2
  • 1 D/O Medical Laboratory Technology, Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia , Jazan (Saudi Arabia)
  • 2 Medical Research Center, Jazan University, Jazan, Saudi Arabia , Jazan (Saudi Arabia)
Type
Published Article
Journal
Applied Biochemistry and Microbiology
Publisher
Pleiades Publishing
Publication Date
Jul 27, 2021
Volume
57
Issue
4
Pages
468–474
Identifiers
DOI: 10.1134/S0003683821040025
Source
Springer Nature
Keywords
Disciplines
  • Article
License
Yellow

Abstract

AbstractNon-enzymatic glycation is a spontaneous and deleterious phenomenon that normally takes place inside human body and causes tissue damage. In the course of glycation reaction between glycating agents and biomolecules, several reactive perilous intermediates and finally heterogeneous group of compounds, advanced glycation end products (AGEs), are generated. Formations of AGEs are accelerated under disease conditions including diabetes and its complications. Endogenous 3-deoxyglucosone (3-DG) is a powerful glycating agent that glycates biomolecules including proteins compromising its structure and functionality. The production of 3-DG is significantly elevated during diabetes leading to vascular damage through glycation reaction. In the present study, human IgG was glycated with 3-DG to examine the AGEs production (Nε-carboxymethyllysine and pentosidine) by probing the degree of side chain modifications, formation of different intermediates and structural alterations induced by 3-DG on IgG. The results point out AGEs formation, intermediates generation (indicating oxidative stress) and structural alteration upon glycation of IgG by 3-DG, which may disturb normal functioning of IgG and compromise immune response in secondary complications of diabetes.

Report this publication

Statistics

Seen <100 times